
CONNOVIA

THE NEED AND OUR APPROACH

Promising science needs a path to patients.



Connovia is building a patient-driven therapeutics accelerator for Marfan syndrome and related genetic connective tissue diseases. Our ambition is to end the harm these diseases cause. We aim to advance medical treatments that protect life and improve how people feel and function every day.

Build on progress. Address what remains.

Surgical advances have made lives possible that once would have been cut short. We are grateful to the clinicians, researchers, patients, and families behind that progress. Yet serious vascular complications and daily burdens across the body remain. Better treatments must address both survival and quality of life.

Our proposed therapeutic focus

Vascular

Advance treatments that could slow or prevent aortic and other vascular disease progression, reduce serious complications, and lessen the need for surgery.

Ocular

Preserve sight and reduce the burden of eye complications associated with these diseases.

Musculoskeletal

Address pain and limitations involving bones, joints, and movement. Improve comfort, mobility, and the ability to participate in school, work, and daily life.

Multisystem

Pursue treatments that address shared disease mechanisms across tissues, with the potential to benefit multiple organ systems and reduce the combined burden of disease.

Different conditions will need different approaches. Patient priorities, scientific evidence, and development feasibility will guide program selection.

1 Define patient priorities → 2 Identify promising science → 3 Establish proof of concept → 4 Partner for further development

Start with patient goals. Work backward.

Goals like walking without pain, preserving sight, and avoiding aortic surgery will guide our research questions and outcomes.

We will bring patients, clinicians, and scientists together to define the problem, assess potential treatments, and identify the critical experiments. Results will determine whether a program advances, changes direction, or stops.

Bridge the Valley of Death.

Promising discoveries can stall when they need more evidence than available research funding can support, while remaining too early for industry investment. Connovia will focus on this translational gap: assembling expertise and raising funding for the studies needed to establish proof of concept. We will seek partners equipped for clinical development, manufacturing, and commercialization.

CONNOVIA

AN INVITATION TO COLLABORATE

Help shape what comes next.

You may see an unmet need in your clinic, have a finding that could lead to treatment, or know a promising program that has stalled. We would welcome a conversation.

What we're looking for

Existing medicines with new potential

Repurposing opportunities that could address disease biology or complications.

Programs that need a path forward

Academic discoveries and therapeutic candidates that need further validation, funding, or a development partner.

New therapeutic approaches

Emerging treatments with the potential to change disease progression, including opportunities requiring longer development timelines.

Where your expertise fits

Clinicians

Identify unmet needs, priorities from clinical practice, and outcomes that would represent meaningful improvement.

Researchers

Share therapeutic hypotheses, findings, disease models, and ideas for experiments that could establish whether an approach works.

Drug developers and industry partners

Help define the evidence needed for further investment and explore programs with potential for this community.

What Connovia will contribute

We will define focused programs around patient needs, coordinate scientific expertise, raise funding for critical studies, and develop partnerships to move strong opportunities forward. Our role is to work with the people behind promising discoveries to establish the next milestone and what it will take to reach it.

We are thinking broadly and creatively about paths to a cure, including approaches emerging beyond the connective tissue disease field. We are exploring how AI and other emerging technologies could help us identify and evaluate therapeutic opportunities at greater scale, with promising leads advanced through expert review and experimental validation.

Where we are today

Connovia is in its founding stage. We are assessing therapeutic opportunities and building scientific relationships. Over the next year, we aim to identify our first priorities, assemble the expertise to pursue them, and raise the funding needed to begin testing the strongest opportunities. Early conversations will help shape those decisions.

About the founder

Allison Pullins brings 20 years of healthcare experience and the perspective of a Marfan parent and longtime patient advocate. She helped build and sell a healthcare technology company (MD Ranger), then led the creation of a commercial technology division within ECG Management Consultants. She now applies that experience to advancing better treatments for her son James and his community.

Let's start a conversation.

Allison Pullins, Founder | allison@connovia.org